Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The market cap is $12 million. If we actually have sales this year of DED tests to ophthalmologists and optometrists and there is a real need for these tests then the valuation could be too low. Janey thinks this is a scam. I see it more as unfortunate the way the NAB test never got used by the public.
What sort of yearly revenues could we hope for from DED? It is a simple test to do in the clinic but there is some question on whether the FDA would require a certified laboratory to do the tests. This uncertainty needs to be cleared up.
Over on Stock Twits a person posted that IKBR is allowing purchase of CATV. I just called and they said no this is not true. The guy even showed a screen shot of his purchase. This whole thing seems odd. The stock price is 0.0008. I would purchase if I could purchase. It trades on the grey market. Is it only Canadians that have an access to the grey market?
No trades today so far. Could we be halted? If the CE were to come off at what time of day would that information be broadcast?
Should Michael Feldenkrais , our CEO , be communicating with his shareholders or is going dark a ominous sign of the future outcome for CATV?
Did the greenhouse roof get repaired? Is the Hip Bistro doing a good business? Perhaps a posted menu from the Hip Bistro would interesting to see.
Buying into the DED business at 5 cents per share might be an opportunity. What does the squirrel think at this juncture?
Inspire 1 and Inspire 2 have taken a long time to complete. We are at 19 of 20 patients in Inspire 2. The patents to protect our intellectual property must now have a limited time left until expiration. Perhaps the new addition of stem cells and nerve growth factors in future trials would extend patent protection for a much longer time. Are we filling for new patents?
I remember seeing a post from Dr. Otiko that the stain free VitaStem product will be available in a few weeks. However that might have been 6 weeks a go or so.
Is there a limitation due to Fair Disclosure requirements for Dr. Otiko to tell investors what is causing a delay?
What is the company’s name in North Carolina that is manufacturing the stain free VitaStem? Are we able to pay them the required money for producing the product?
What sort of price target are investors and speculators putting on WHSI. At 4 cents there was a sudden sell off. I wish I had decided to sell at 0.04. Other posters have said $1.00 is a possibility. We have suffered dilution recently. That would mean everybody would need to lower their price target for WHSI.
When do we get to see the Kathy Ireland promotions for WHSI health protection products?
Is there no scientific credibility for the 4 DED tests and the testing accuracy? Why is it specifically that this would be known to be a scam? I think there is a need for accurate testing for DED. It is not always an easy disease to diagnose. Paradoxically many patients experience excessive tearing.
I agree however that the price performance of the stock is consistent with how a scam stock would perform if investors thought it was a scam.
I see 2 trades for 10,000 shares at 0.0001. Is that worth $2.00?
Do we know who is manufacturing the stain free VitaStem?
The Market Cap is around $9 million. What sort of annual DED test sales could be in the ballpark for AXIM? If sales were growing rapidly what sort of pps could be justified? Thanks
It is a product that works. It is a product that people want. The issue seems to be logistics. Dr. Otiko is doing this whole thing by himself it seems.
Did the quarterly financial report released today cause any new concerns or reasons for optimism? It could be a profitable company with an actual execution of the business plan.
Now the market cap is $4.9 million. If Inspire 2.0 is a success that would be worth how much. After this comes stem cells and nerve growth factors in addition to the Spinal scaffold implant.
I think we have enough cash to finish the Inspire 2.0.
We have more cash on hand than the market cap of the company. Does that mean that our intellectual property is worth nothing or less than nothing?
Who is it that has the authority to make the CE removal decision? What sort of documentation must be properly presented? Are we linked specifically to the Svorai case proceedings?
Specifically it is the stain free tetracycline product that penetrates the dermal layers better than competitor products do that could see a sizable market demand.
A lot of people saw what happened in Jan and Feb of 2021. Was that 30x in one month? How often does that happen? Selling at that relatively brief momentary crest is the key skill to have.
I do not yet have that quick timely selling talent. Also you can almost always buy it back again later for cheaper if you want to stay with the stock.
There is Amazon resupply, hospital contracts, state by state revenues. There were other products to launch.
Is there a future date to look out for when the CE decision could be considered with adequate established information?
I am amazed that LPCN is now 0.92. Testosterone replacement therapy is a large market. Will sales disappoint for a reason?
Is Vyleesi a product potentially delivered in a patch. Are there countries where men can use Vyleesi?
SAVA is working on a test to detect early onset Alzheimer’s before it is debilitating. If there is also a treatment to prevent Alzheimer’s this would be a wonderful combination of products.
If there were no effective treatment for Alzheimer’s then a reliable positive test would be a lifestyle choice worse than having no such knowledge since no knowledge would be a relatively more blissful state of mind.
Absolutely great post MallenNV. Since this is all legal, there could be schools charging a tuition to teach new young scammers how to do the exact same highly profitable scam you delineate.
Your book will be a great one. I want to order a copy for myself. It has been fun to follow SGMD and your commentary and how you profited from being short.
My question still is how it is that you went short without the sort of very high margin requirement that a brokerage house establishes. This margin seems to reflect a massive risk in being short if there would be a spike up in price. This protects the brokerage from any losses.
Thanks again.
The market cap is $7 million. If Inspire 2 gets fully enrolled and is successful what would be the market cap? The company has two or three times the market cap in cash. One year or so of cash burn runway.
Why are the CEO salaries so high?
Did Bignutz get sued personally for the money owed to our OWCP employees and creditors that never got paid? Might a judge want to see a full accounting of the $5 million toxic loan proceeds?
What will happen to the IP? Is it worth anything? Does the cannabis cream actually effectively help psoriasis and other skin conditions? How hard would it be to enforce the patent against competitors infringing on the patent. Can the IP be bought if someone wanted to own the patent? Thanks
What is the relationship of these retractions to our phase 3 clinical trials? My understanding is that our MOA is assisting the proper folding of proteins in the endoplasmic reticulum. I do not have access to the SA article. Not a member there. Can someone repost the key bits of information here? Thanks
Could it be the Dry Eye treatment that has sparked an interest here? There is also an IBD treatment in trials? Vyleesi also works in men which would be a large market. A Vyleesi patch if possible would avoid the needle that limits demand for this sort of nonessential product.
The 35 patients I think are a total of Inspire 1.0 and Inspire 2.0 patients. It was 15 patients in Inspire 1.0 when a patient died that was later determined not to be due to the NSS implantation. The FDA at the time also wanted a control arm that we did not have in Inspire 1.0.
Inspire 2.0 is 20 patients total of which 17 have enrolled to date that we know of. 15 + 20 = 35. This is how I see the meaning of the total number of patients having a total of 35.
The FDA forced AXIM to go qualitative and then changed their mind to quantitative.
If the answer from OTC about CE is no, how long until an appeal could be filed for the second time?
Could OTC have a liability risk for damaging a legitimate business?
Perhaps Dr. Otiko has to be very careful about not accidentally revealing any inside information. By being entirely quiet and saying absolutely nothing he can be assured that he is not breaking any securities laws.
He is not a lawyer so may not know what can be said safely and what could cause problems.
Have we started manufacture of the DED kits? I saw the interview and he is working on DED primarily. What needs to happen before sales occur? He also mentioned oncology diagnoses and treatment.
If omicron type 2 causes spike #4 there will be a question whether 3 shots offers sufficient neutralizing antibodies. Memory T Cells are also involved in immunity. The question might be who needs a 4Runner shot and who does not need it.
A quick at home test of your own level of neutralizing antibodies would help both you and your physician make decisions that are instrumental in minimizing future morbidity and mortality for the patient and the related costs to society.
I don’t understand the bypass of short registration. You said you can short the shares as a long. Being long and being short seem to be two opposite things.
How does a retail person short SGMD without borrowing the shares with a margin account and putting up the required margin?
Then there is the subject of naked shorts. I didn’t think that small retail people could do a naked short which I think means that they did not register.
This particular stock does go continuously down and never ever has a run that could threaten a short position.
Thanks
This is up 40% in two months during a severe micro cap sell off. Positive relative strength.
Going short SGMD requires margin with a brokerage. It is considered to be highly risky to short Penny stocks.
What is the ball park margin that gets put up for a short position in SGMD after the reverse split but before the subsequent sell off to 0.0005 again?
Thanks
3a10 toxic convertible loans are what destroy many micro cap companies. You are saying that the CEOs and other officers are all in on it. Even the OTC is in on the scam and profits massively from it. This story deserves to be told.
Why can’t a company simply sell shares that are beneath the authorized share limit and use that money to become a successful business? Is there a list of any or many stinky pinky success stories? Does it ever happen?
Can toxic funding be replaced by company share selling or better quality lending? Should or could OTC stocks have a toxic financing rating attached to them as an investor caveat emptor? Thanks
An EUA could get pulled perhaps once an emergency situation is over. Did we also apply for normal approval? If the test is accurate what would hold up approval? The FDA has the responsibility to protect the safety of the public. How does an accurate medical test cause harm?
What are the products that are in direct competition with the WHSI health monitoring product for the elderly?
I am in this still hoping that Inspire 2.0 is a success similar to Inspire 1.0. Then after approval by the FDA the addition of stem cells and/or nerve growth factors could help patients even better perhaps.
Growing neural connections could have applications beyond spinal cord injury.
Connecting computer interfaces to the brain may also use similar technology.
What surprises me is that there is so little interest in NVIV and so little hope for success. Early investors have been wiped out entirely. The latest investors are also bag holders. The CEO makes more than $1million per year.
Is the CEO that you met in 2012 now in prison?
The run last ear from 0.0007 to 0.07 happened also after an extended quiet period. It also coincided with a run in micro cap at that time in general.
Market conditions are poor for a run at this time. Perhaps it is best to wait for a more auspicious time to present positive news or a PR or even any forward looking intentions or prospects.
Thanks MallenNV. This post of yours is great information and writing. American Greed on CNBC might want to look at this as a good example of stinky pinky corruption. They do some excellent corruption reporting. You could offer perhaps to be a consultant for the show.
Can you think of any legislation that could be passed that would better protect investors in micro cap companies?
The convertible debt holders are the smart money. This is easy money for them. Could micro cap companies get funded in a less toxic and corrupt manner?
Is the 94% to 97% accuracy rate considered good enough? With antigen tests I saw accuracy rates of around 80%
We are showing levels of neutralizing antibodies. The antigen tests either detect or do not detect antigen. ImmunoPass is a quantitative test as well.
One issue for the FDA could be that the scientists have not yet agreed on what is a protective level of neutralizing antibodies to have and maintain.
What harm could be caused by letting people have this information? The benefit to people seems obvious.
This is now a falling knife. 300,000 on the ask. 5,000 on the bid. MC is $22 million Does the cancer test part of AXIM have much hope or value for the company? DED revenue should stabilize sentiment at some point it would seem.